NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Growth Hormone, Longevity & Anti-Aging/CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin

Research combination of a long-acting GHRH analog (CJC-1295) and a ghrelin-mimetic secretagogue (Ipamorelin), used off-label to stimulate the growth hormone axis.

Overview

This entry covers the research-use combination of CJC-1295 and ipamorelin, two synthetic peptides acting on different points of the growth hormone (GH) axis. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH), developed with drug-affinity-complex (DAC) technology intended to prolong its action; ipamorelin is a synthetic ghrelin-mimetic growth hormone secretagogue with selectivity for the GH secretagogue receptor.

The combination is used in research and off-label contexts on the rationale that stimulating both GHRH- and ghrelin-type pathways produces more robust GH pulses. Published human data on the combination itself are scarce, although the individual components have reached early clinical testing in other contexts.

Mechanism

CJC-1295 activates the GHRH receptor on pituitary somatotrophs, increasing the amplitude of GH pulses. Ipamorelin mimics ghrelin's action at the GH secretagogue receptor, augmenting GH release through a complementary pathway.

Note that some vendors supply CJC-1295 without the DAC modification; that form behaves more like the shorter-acting GHRH(1-29) peptide (Mod GRF 1-29) and should not be assumed equivalent to the DAC-conjugated version.

Dosing

No approved or validated dosing exists. In research-vendor use, both peptides are given by subcutaneous injection, with protocols varying widely.

  • Subcutaneous administration of both peptides in typical research use
  • CJC-1295 (DAC form) is designed for less frequent dosing than non-DAC GHRH analogs
  • Ipamorelin is often dosed more frequently in self-reported protocols; none of these regimens is clinically validated

Expected Effects

  • Increased GH pulse amplitude reported in early clinical pharmacology work with DAC-modified CJC-1295
  • GH-releasing activity of ipamorelin demonstrated in animal and clinical pharmacology studies
  • Effects of the specific combination on body composition have not been established in controlled trials

Side Effects & Tolerability

Theoretical concerns center on the expected effects of elevated GH, such as fluid retention, joint discomfort, and effects on glucose metabolism; injection-site reactions are also possible. Safety of the specific combination has not been formally studied.

Storage

Both peptides are typically supplied lyophilized; store frozen, desiccated, and protected from light, and follow each supplier's reconstitution guidance.

Related peptides

Advanced Senolytic Peptide VariantsVendor category for peptides promoted as senolytic agents for clearing senescent cells; specific products are not identified in the literature.AOD-9604Synthetic 15-amino-acid peptide based on the C-terminal lipolytic region of human growth hormone; clinical development for obesity was not completed.Chronobiology Master Regulator AnalogsMarketing-style name implying circadian-regulation peptides; no such products are described in the literature.Comprehensive Longevity Peptide Complex AnalogsVendor complex blend marketed for longevity support; composition is undocumented and unstudied.Epitalon (Expanded)Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the Khavinson group; reported effects on pineal function and telomerase activity remain largely unreplicated.FOXO3a Activator Peptide AnalogsSpeculative category of peptides claimed to activate FOXO3a signaling; no specific products are described in the literature.